GeoVax Labs, Inc. (GOVX)

NASDAQ: GOVX · IEX Real-Time Price · USD
1.08
+0.03 (2.86%)
At close: Sep 27, 2022 4:00 PM
1.09
+0.01 (0.93%)
After-hours: Sep 27, 2022 4:10 PM EDT
2.86%
Market Cap 26.72M
Revenue (ttm) 276,902
Net Income (ttm) -20.36M
Shares Out 24.74M
EPS (ttm) -2.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 621,836
Open 1.09
Previous Close 1.05
Day's Range 1.06 - 1.12
52-Week Range 0.55 - 5.61
Beta 3.31
Analysts Buy
Price Target 6.12 (+466.7%)
Earnings Date Nov 9, 2022

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership... [Read more...]

Industry Biotechnology
Founded 2001
CEO David Dodd
Employees 11
Stock Exchange NASDAQ
Ticker Symbol GOVX
Full Company Profile

Financial Performance

In 2021, GeoVax Labs's revenue was $385,501, a decrease of -78.86% compared to the previous year's $1.82 million. Losses were -$18.57 million, 527.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for GOVX stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 466.67% from the latest price.

Price Target
$6.12
(466.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine (GEO-CM04S1) and Phase 1/2 Clinical Trial for Advanced Head and Neck Cancer (Gedeptin ® )

2 weeks ago - GlobeNewsWire

GeoVax Announces Addition to Its Board of Directors

Nicole Lemerond, CFA, Brings Healthcare Finance Expertise to the GeoVax Board

3 weeks ago - GlobeNewsWire

GeoVax Labs Stock Is a Monkeypox Meme Play for Bold Traders

GeoVax Labs (NASDAQ: GOVX ) recently released its second-quarter 2022 financial results. Some investors might object to GeoVax's net earnings loss.

1 month ago - InvestorPlace

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer ...

1 month ago - InvestorPlace

GeoVax Labs Stock Has a Lot More Than Hype Behind Its Recent Surge

GeoVax Labs (NASDAQ: GOVX ) stock has gone parabolic and it's easy to see why. As the extent of the 2022 monkeypox outbreak keeps getting worse, this virus continues to be at the top of the headlines.

1 month ago - InvestorPlace

3 Monkeypox Stocks to Buy as Biden Declares Public Health Emergency

The White House has declared monkeypox a public health emergency. Within the last two weeks, California, New York and Illinois making the same declaration already, and many other states are sounding the...

Other symbols: APDNBVNRY
1 month ago - InvestorPlace

GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology

1 month ago - GlobeNewsWire

Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears

Monkeypox stocks are rallying amid worries about a shortage of vaccines for the illness in the U.S. Additionally, in recent days, New York state, New York City and San Francisco have issued emergency or...

Other symbols: SIGAVRAX
1 month ago - InvestorPlace

GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Eb...

ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...

1 month ago - GlobeNewsWire

GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update

Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time

2 months ago - GlobeNewsWire

Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency

Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. The post Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Heal...

Other symbols: BVNRYCMRXEBSSIGA
2 months ago - InvestorPlace

Why Is GeoVax (GOVX) Stock Up 90% Today?

GOVX stock is soaring in early trading after WHO declared monkeypox a global health emergency over the weekend. The post Why Is GeoVax (GOVX) Stock Up 90% Today?

2 months ago - InvestorPlace

Two Pharma Companies That Will Profit From The MonkeyPox Outbreak

The monkeypox outbreak has affected 780 people since identified on May 13, 2022. Vaccines are key to curtailing the spread of Monekey Pox. Two pharma companies, Geovax Labs Inc. and Emergent Biosolution...

Other symbols: EBS
3 months ago - The Dog of Wall Street

GeoVax to Present at BIO International Convention 2022

Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin®

3 months ago - GlobeNewsWire

GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules

Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announc...

4 months ago - GlobeNewsWire

7 Monkeypox Stocks to Watch Right Now

Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus.

4 months ago - InvestorPlace

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China

Atlanta, GA, May 24, 2022 (GLOBE NEWSWIRE) -- IND-Enabling Studies Underway in the United States for MVA-VLP-MUC1 Vaccine Candidate

4 months ago - GlobeNewsWire

Why Is GeoVax (GOVX) Stock Up 25% Today?

GOVX stock is jumping on the firm's 2020 statement that the "basis" of its vaccine vector was approved as for monkeypox prevention. The post Why Is GeoVax (GOVX) Stock Up 25% Today?

4 months ago - InvestorPlace

GeoVax Announces Upcoming Presentations at Scientific Conferences

ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ca...

4 months ago - GlobeNewsWire

GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update

Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology

5 months ago - GlobeNewsWire

GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate

The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ: GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite.

5 months ago - Benzinga

GeoVax Announces Issuance of Malaria Vaccine Patent

GeoVax's Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria

5 months ago - GlobeNewsWire

GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update

Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time

5 months ago - GlobeNewsWire

GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress

Company's COVID-19 Vaccine Candidate GEO-CM04S1 Continues to Advance in COVID-19 Phase 2 Clinical Trials While the Experimental Universal Vaccine Candidate GEO-CM02 Demonstrated Single-Dose, 100% Protec...

5 months ago - GlobeNewsWire

GeoVax Announces Issuance of Cancer Vaccine Patent

IND-Enabling Studies Underway for MVA-VLP-MUC1 Vaccine Candidate

6 months ago - GlobeNewsWire